HOSTED BY BANNER ALZHEIMER'S INSTITUTE
Kamloops BC VC2 1K7
Canada
Men and women who have been experiencing gradual and progressive change in memory function over more than 6 months.
The AMARANTH Study is a clinical research study for men and women who may have early
Alzheimer’s disease. It is being conducted worldwide to find out if the investigational drug is safe and effective in slowing down the progression of the disease.
The purpose of the study is to determine if the investigational medication, AZD3293 [LY3314814] is safe and effective in slowing down the progression of the disease. In Alzheimer’s disease, plaques and tangles are created in the brain. They cause your brain to gradually work less well, which means you have difficulty in thinking, learning, and remembering things.
The plaques are made out of sticky substance called amyloid. The investigational drug is designed to reduce the creation of substances that will eventually become amyloid and it may therefore slow down the deterioration of the brain in people with early Alzheimer’s disease.
This study will test if this actually occurs.
The AMARANTH Study will last approximately two years. During the screening period, which will take about 8 weeks, participants will undergo physical examinations and cognitive testing.
Additionally, there will be either a PET scan, or CSF sample, taken to determine study eligibility.
There are 21 scheduled visits during the study; 17 will take place at the clinic and 4 will be conducted by telephone with the study participant, and his or her study partner.
Kamloops BC VC2 1K7
Canada